| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC20436 | Lin28-IN-1 | Lin28-IN-1 is a small-molecule inhibitor of the Lin28/let-7 interaction with IC50 of 4.03 uM. |
|
| DC20982 | Linopirdine dihydrochloride | Linopirdine (DUP-996) is a potent Kv7 (KCNQ) voltage-gated potassium channels blcoker. |
|
| DC20983 | Linopirdine | Linopirdine (DUP-996. |
|
| DC26056 | Liproxstatin-1 analog | Liproxstatin-1 analog is an analog of the ferroptosis inhibitor liproxstatin-1 |
|
| DC23664 | Lirimilast | Lirimilast (BAY 19-8004. |
|
| DC12434 | LIT-001 trifluoroacetate Featured | LIT-001 trifluoroacetate (LIT001) is the first nonpeptide Oxytocin receptor (OT-R) agonist with EC50 of 55 nM, Emax=96%. |
|
| DC8689 | Litronesib | Litronesib is a selective, allosteric inhibitor of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing. |
|
| DC4138 | Lixivaptan (VPA-985) Featured | Lixivaptan is a highly potent, non-peptide, oral capsule that works by reducing the action of a hormone (vasopressin) that blocks fluid excretion. |
|
| DC21233 | LJ 001 Featured | LJ 001 ((LJ-001, LJ001) is a broad-spectrum antiviral agent targeting entry of enveloped viruses, including influenza A, filoviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, and HIV-1; specifically intercalates into viral membranes, irreversibly inactivates virions while leaving functionally intact envelope proteins, and inhibits viral entry at a step after virus binding but before virus-cell fusion; specifically inhibits virus-cell but not cell-cell fusion |
|
| DC12172 | L-JNKI-1 | L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK. |
|
| DC21234 | LKY-047 | LKY-047 is a decursin derivative that potently and selectively inhibits CYP2J2, competitively inhibits CYP2J2-mediated astemizole O-demethylase and terfenadine hydroxylase activity with Ki of 0.96 and 2.61 uM, respectively. |
|
| DC21235 | LLL3 | LLL3 is a structural analogue of STA-21 that acts as a novel STAT3 inhibitor, inhibits STAT3-dependent transcriptional and DNA binding activities. |
|
| DC20438 | LLP2A | LLP2A is a high-affinity, selective peptidomimetic ligand of α4β1 integrin with IC50 of 2 pM. |
|
| DC21237 | LLS2 | LLS2 is a novel potent Galectin-1 (Gal1) inhibitor that decreases membrane-associated H-Ras and K-Ras and contributed to the suppression of pErk pathway. |
|
| DC21238 | LLS30 | LLS30 is a potent, allosteric Galectin-1 (Gal-1) inhibitor, inhibits AR negative cells PC3, DU145, and AR positive cells, 22RV1 and CWR-R1 cells with IC50 of 10.4 μM, 5.3 μM, 3.3 μM and 5.9 μM, respectively. |
|
| DC21239 | LLY-2707 | LLY-2707 (LLY 2707, LLY2707) is a novel potent, selective, nonsteroidal glucocorticoid receptor antagonist with Ki of 2.13 nM. |
|
| DC21240 | LLY-283 Featured | LLY-283 (LLY283) is a potent, selective inhibitor of arginine methyltransferase 5 (PRMT5) with IC50 of 22 nM. |
|
| DC23127 | LMD-009 | LMD-009 (LMD 009, LMD009) is a potent, selective, nonpeptide CCR8 agonist that stimulates CCR8-mediated chemotaxis, inositol phosphate accumulation and calcium release with EC50 of 11-87 nM. |
|
| DC11148 | LMD-A | LMD-A (CCR8 antagonist LMD-A) is a highly potent, small molecule antagonist of chemokine receptor CCR8 with EC50 of 2.5 nM. |
|
| DC20259 | LML134 Featured | LML134 (compound 18b) is an orally active and high selective Histamine 3 receptor (H3R) inverse agonist with Kis of 0.3 nM and 12 nM for hH3R cAMP and hH3R bdg. LML134 penetrates the brain rapidly, leading to high H3R occupancy, and disengages its target with a fast kinetic profile. LML134 has the potential for excessive sleep disorders[1]. |
|
| DC12602 | LMT-28 Featured | LMT-28 (LMT28) is a specific blocker of IL-6 signaling via inhibits IL-6Rβ (gp130) with IC50 of 5.9 uM (IL-6–induced luciferase activity), selectively inhibits IL-6–induced phosphorylation of STAT3, JAK2, and gp130. |
|
| DC21247 | LN-1-255 | LN-1-255 is a 6-alkylidene-2'-substituted penicillin sulfone that acts as an effective beta-lactamase inhibitor. |
|
| DC12324 | Loganetin | Loganetin is a non-toxic natural product that may be applied in the antibacterial drug development for treating multidrug-resistant Gram negative infections. |
|
| DC12142 | LOM612 | LOM612 is a potent activator of FOXO nuclear translocation, with an EC50 value of 1.5 μM in cells. |
|
| DC7778 | Lometrexol(LY 264618) Featured | Lometrexol is a tight-binding antifolate inhibitor of the purine de novo enzyme glycinamide ribonucleotide formyltransferase (GARFT), was the first GARFT inhibitor to be investigated clinically. |
|
| DC21250 | Lopixibat chloride | Lopixibat chloride (LUM-001, HP-625) is a potent, selectiove, oral inhibitor of sodium bile acid cotransporter and Ileal bile acid transporter (IBAT).. |
|
| DC8645 | Lorcaserin hydrochloride heMihydrate | Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. |
|
| DC10254 | L-Ornithine | L-ornithine has an antifatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia. It is one of the key reactants in the urea cycle. |
|
| DC7711 | Losmapimod Featured | Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3. |
|
| DC23403 | LP99 Featured | LP99 is the first potent and selective BRD7/9 bromodomain inhibitor with Kd of 99 nM for BRD9. |
|
